The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
SARS-CoV-2 vaccines in development
Open accessAbstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed: a phase I trial started in March 2020 and there are currently more than 180 vaccines at various stages of development. Data from phase I and phase II trials are already available for several vaccine candidates, and many have moved into phase III trials. The data available so far suggest that effective and safe vaccines might become available within months, rather than years.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential advantages of inactivated vaccines are non-replicability in the host, non-transmissibility, and the induction of a broad range of humoral and cellular responses against different epitopes.”
In the citing paper
“Their production and scale-up are relatively easy in the context of good yield production systems and the availability of biosafety level 3 facilities.7”
In the citing paper
“8 weeks after the second vaccine injection volunteers showed high levels of IgM, and IgG anti-SARS-CoV-2 spike protein (S) and receptor binding domain (RBD) binding titers3,5,6.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [3]
In the citing paper
“In agreement with previous reports3,6,9, there was a broad range of plasma neutralizing activity 3–14 weeks after the second vaccine dose that was similar to that elicited by natural infection in a convalescent cohort after 1.3 months, and greater than the activity at 6.2 months after infection (Fig. 1a, Extended Data Table 1).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [3]
In the citing paper
“In line with previous reports3,6,9, IgG and IgM levels were significantly higher in the vaccinated group compared to a cohort of convalescent patients assayed 1.3 and 6.2 months after infection, while IgA levels were similar (Extended Data Fig 1j–l).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [3]
In the citing paper
“However, this and other small studies3,11 cannot accurately predict the half-life of the neutralizing response.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [3]
In the citing paper
“Humans make SARS-CoV-2-specific antibodies, CD4+ T cells, and CD8+ T cells in response to SARS-CoV-2 infection (Grifoni et al., 2020; Krammer, 2020; Stephens and McElrath, 2020) (Figure 1).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Krammer, 2020
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Origin and evolution of pathogenic coronaviruses
Cui, J., Li, F., & Shi, Z. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,729
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2
Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,952
Research works printed but not linked: 1
- The National Academies of Sciences, Engineering and Medicine. Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine (The National Academies Press, 2020).
Cited by
Sorted by citations
Items 301–400 of 1,004
Schmidt, A., Helgers, H., Vetter, F. L., Juckers, A., & Strube, J. (2021) · Processes · doi:10.3390/pr9050748 · Cited by 55
Monitor for COVID-19 vaccine resistance evolution during clinical trials
Kennedy, D. A., & Read, A. F. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3001000 · Cited by 54
Correlates of Vaccine-Induced Protection against SARS-CoV-2
Koch, T., Mellinghoff, S. C., Shamsrizi, P., Addo, M. M., & Dahlke, C. (2021) · Vaccines · doi:10.3390/vaccines9030238 · Cited by 57
Watterson, D., Wijesundara, D. K., Modhiran, N., Mordant, F. L., Li, Z., Avumegah, M. S., McMillan, C. L. D., Lackenby, J. A., Guilfoyle, K. A., van Amerongen, G., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1269 · Cited by 53
Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2
Park, J.-G., Oladunni, F. S., Rohaim, M. A., Whittingham‐Dowd, J., Tollitt, J., Hodges, M., Fathallah, N., Assas, M. B., Alhazmi, W. A., Almilaibary, A., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102941 · Cited by 54
Valckx, S., Crèvecoeur, J., Verelst, F., Vranckx, M., Hendrickx, G., Hens, N., Damme, P. V., Pepermans, K., Beutels, P., & Neyens, T. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.073 · Cited by 53
Liu, K., Han, Y.-J., Wu, G.-H., Huang, K.-Y. A., & Huang, P.-N. (2022) · Viruses · doi:10.3390/v14071560 · Cited by 57
Dynamics of antibody response to CoronaVac vaccine
Fonseca, M. H. G., de Souza, T. D. F. G., Araújo, F. M. D. C., & de Andrade, L. O. M. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27604 · Cited by 52
Shiakolas, A. R., Kramer, K. J., Johnson, N. V., Wall, S. C., Suryadevara, N., Wrapp, D., Periasamy, S., Pilewski, K. A., Raju, N., Nargi, R. S., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01232-2 · Cited by 52
Almofti, Y., Abd-elrahman, K. A., & Eltilib, E. E. M. (2021) · BMC Immunology · doi:10.1186/s12865-021-00412-0 · Cited by 50
COVID-19 vaccine testing in pregnant females is necessary
Klein, S. L., Creisher, P. S., & Burd, I. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147553 · Cited by 55
Lombardi, A., Bozzi, G., Ungaro, R., Villa, S., Castelli, V., Mangioni, D., Muscatello, A., Gori, A., & Bandera, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657711 · Cited by 51
Charge‐Conversion Strategies for Nucleic Acid Delivery
Dutta, K., Das, R., Medeiros, J., Kanjilal, P., & Thayumanavan, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202011103 · Cited by 52
Kiener, M., Roldán, N., Machahua, C., Sengupta, A., Geiser, T., Guenat, O. T., Funke-Chambour, M., Hobi, N., & Julio, M. K. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.644678 · Cited by 52
English, E., Cook, L. E., Piec, I., Dervisevic, S., Fraser, W. D., & John, W. G. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00288-21 · Cited by 52
Chasaide, C. N., & Mills, K. H. G. (2020) · Vaccines · doi:10.3390/vaccines8040621 · Cited by 54
Molecular and Biological Mechanisms Underlying Gender Differences in COVID-19 Severity and Mortality
Wehbe, Z., Hammoud, S. H., Yassine, H. M., Fardoun, M., EL‐Yazbi, A. F., & Eid, A. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.659339 · Cited by 54
Kim, D. S., Rowland‐Jones, S., & Gea‐Mallorquí, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571481 · Cited by 51
Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
Carbone, M., Lednicky, J. A., Xiao, S., Venditti, M., & Bucci, E. M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.014 · Cited by 62
Innovations and development of Covid-19 vaccines: A patent review
Alshrari, A. S., Hudu, S. A., Imran, M., Asdaq, S. M. B., Alreshidi, M. A., & Rabbani, S. I. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.10.021 · Cited by 54
Liu, W., Yang, C., Liao, Y., Wan, F., Lin, L., Huang, X., Zhang, B., Yuan, Y., Zhang, P., Zhang, X., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.11.012 · Cited by 51
An inhaled bioadhesive hydrogel to shield non-human primates from SARS-CoV-2 infection
Mei, X., Li, J., Wang, Z., Zhu, D., Huang, K., Hu, S., Popowski, K. D., & Cheng, K. (2023) · Nature Materials · doi:10.1038/s41563-023-01475-7 · Cited by 53
Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19
Malinowska, B., Baranowska‐Kuczko, M., Kicman, A., & Schlicker, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041986 · Cited by 50
Alkharaan, H., Bayati, S., Hellström, C., Aleman, S., Olsson, A., Lindahl, K., Bogdanović, G., Healy, K., Tsilingaridis, G., Palma, P., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab256 · Cited by 51
An Update on mRNA-Based Viral Vaccines
Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 49
Mitsi, E., Reiné, J., Urban, B. C., Solórzano, C., Nikolaou, E., Hyder-Wright, A. D., Pojar, S., Howard, A., Hitchins, L., Glynn, S., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157124 · Cited by 50
COVID-19 vaccines in pregnancy
Nunes, M. C., & Madhi, S. A. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.04.012 · Cited by 53
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
Ponce‐de‐León, S., Torres, M., Soto-Ramírez, L. E., Calva, J. J., Santillán‐Doherty, P., Carranza-Salazar, D. E., Carreño, J. M., Carranza, C., Juárez, E., Carreto-Binaghi, L. E., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00662-6 · Cited by 70
Self-citationEllis, D., Brunette, N., Crawford, K. H. D., Walls, A. C., Pham, M. N., Chen, C., Herpoldt, K., Fiala, B., Murphy, M., Pettie, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710263 · Cited by 45
Meir, J., Abid, M. A., & Abid, M. B. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.09.016 · Cited by 51
van Doremalen, N., Purushotham, J. N., Schulz, J. E., Holbrook, M. G., Bushmaker, T., Carmody, A., Port, J. R., Yinda, C. K., Okumura, A., Saturday, G. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.09.426058 · Cited by 50
Self-citationValdez‐Cruz, N. A., García‐Hernández, E., Espitia, C., Cobos-Marín, L., Altamirano, C., Bando-Campos, C. G., Cofas‐Vargas, L. F., Coronado-Aceves, E. W., González-Hernández, R. A., Hernández‐Peralta, P., et al. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01576-5 · Cited by 52
An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages
Motamedi, H., Ari, M. M., Dashtbin, S., Fathollahi, M., Hossainpour, H., Alvandi, A., Moradi, J., & Abiri, R. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107763 · Cited by 51
Jafari, A., Pouya, F. D., Niknam, Z., Abdollahpour‐Alitappeh, M., Rezaei–Tavirani, M., & Rasmi, Y. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07132-7 · Cited by 52
Campuzano, I. D. G., & Sandoval, W. N. (2021) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.1c00036 · Cited by 51
Wong, T. Y., Lee, K. S., Russ, B. P., Horspool, A. M., Kang, J. H., Winters, M. T., Wolf, M. A., Rader, N. A., Miller, O. A., Shiflett, M., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00451-7 · Cited by 49
Mannar, D., Saville, J. W., Zhu, X. Q., Srivastava, S. S., Berezuk, A., Tuttle, K. S., Marquez, C., Sekirov, I., & Subramaniam, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.19.473380 · Cited by 49
CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
Hoffmann, D., Corleis, B., Rauch, S., Roth, N., Mühe, J., Halwe, N. J., Ulrich, L., Fricke, C., Schön, J., Kraft, A., et al. (2021) · doi:10.1101/2021.03.22.435960 · Cited by 48
Danese, E., Montagnana, M., Salvagno, G. L., Gelati, M., Peserico, D., Pighi, L., NITTO, S. D., Henry, B. M., Porru, S., & Lippi, G. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0339 · Cited by 51
Vaccine allergy: evidence to consider for COVID-19 vaccines
Nilsson, L. E., Csuth, Á., Storsæter, J., Garvey, L. H., & Jenmalm, M. C. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000762 · Cited by 48
Network models to evaluate vaccine strategies towards herd immunity in COVID-19
Tetteh, J. N. A., Nguyễn, V. K., & Hernandez-Vargas, E. A. (2021) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.110894 · Cited by 51
Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization
Cheng, Z. J., Huang, H., Zheng, P., Xue, M., Ma, J., Zhan, Z., Gan, H., Zeng, Y., Lin, R., Li, S., et al. (2022) · Allergy · doi:10.1111/all.15271 · Cited by 49
Kar, S., Devnath, P., Emran, T. B., Tallei, T. E., Mitra, S., & Dhama, K. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.604 · Cited by 42
Dahlgren, M. W., Plumb, A. W., Niss, K., Lahl, K., Brunak, S., & Johansson‐Lindbom, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.932388 · Cited by 48
COVID-19 and Pediatric Asthma: Clinical and Management Challenges
Boechat, J. L., Wandalsen, G. F., Kuschnir, F. C., & Delgado, L. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18031093 · Cited by 50
Peros, C. S., Dasgupta, R., Kumar, P., & Johnson, B. A. (2021) · Environmental Science & Policy · doi:10.1016/j.envsci.2021.05.025 · Cited by 51
Zhou, R., Wang, P., Wong, Y.-C., Xu, H., Lau, S.-Y., Liu, L., Mok, B. W.-Y., Peng, Q., Liu, N., Woo, K. F., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103762 · Cited by 50
Chen, Y., Sun, L., Ullah, I., Beaudoin-Bussières, G., Anand, S. P., Hederman, A. P., Tolbert, W. D., Sherburn, R. T., Nguyen, D. N. P., Marchitto, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn4188 · Cited by 49
Alhumaid, S., Mutair, A. S. A., Alawi, Z. A., Alhmeed, N., Zaidi, A. R. Z., & Tobaiqy, M. A. (2020) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed5040180 · Cited by 48
Implications of the Emergence of a New Variant of SARS-CoV-2, VUI-202012/01
Rahimi, F., & Abadi, A. T. B. (2021) · Archives of Medical Research · doi:10.1016/j.arcmed.2021.01.001 · Cited by 46
SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention
Inchingolo, A. D., Inchingolo, A. M., Bordea, I. R., Malcangi, G., Xhajanka, E., Scarano, A., Lorusso, F., Farronato, M., Tartaglia, G. M., Isacco, C. G., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9030525 · Cited by 49
Prompetchara, E., Ketloy, C., Tharakhet, K., Kaewpang, P., Buranapraditkun, S., Techawiwattanaboon, T., Sathean-anan-kun, S., Pitakpolrat, P., Watcharaplueksadee, S., Phumiamorn, S., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248007 · Cited by 47
Puente, J. H. L., Carreño, J. M., Sun, W., Suárez-Martínez, A., Ramírez-Martínez, L. A., Quezada-Monroy, F., la Rosa, G. P.-D., Vigueras-Moreno, R., Singh, G., Rojas-Martínez, O., et al. (2021) · mBio · doi:10.1128/mbio.01908-21 · Cited by 46
Self-citationImmunity to SARS-CoV-2: Lessons Learned
FERGIE, J. E., & Srivastava, A. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654165 · Cited by 46
The Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?
Guo, S., Liu, K., & Zheng, J. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59137 · Cited by 46
Duong, T. V., Lin, C.-Y., Chen, S., Huang, Y., Okan, O., Dadaczynski, K., & Lai, C.-F. (2021) · Vaccines · doi:10.3390/vaccines9090985 · Cited by 50
Seow, J., Khan, H., Rosa, A., Calvaresi, V., Graham, C., Pickering, S., Pye, V. E., Cronin, N., Huettner, I., Malim, M. H., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111276 · Cited by 41
Zhang, J., Xu, Y., Chen, M., Huang, Y., Song, T., Yang, C. J., Yang, Y., & Song, Y. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c09229 · Cited by 46
Machine learning identifies T cell receptor repertoire signatures associated with COVID-19 severity
Park, J. J.-Y., Lee, K. A. V., Lam, S. Z., Moon, K. S., Fang, Z., & Chen, S. (2023) · Communications Biology · doi:10.1038/s42003-023-04447-4 · Cited by 46
Aptamer-based assembly systems for SARS-CoV-2 detection and therapeutics
Dong, Y., Wang, J., Chen, L., Chen, H., Dang, S., & Li, F. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00774j · Cited by 46
Biomimetic Nanomaterial Strategies for Virus Targeting: Antiviral Therapies and Vaccines
Jackman, J. A., Yoon, B. K., Ouyang, L., Wang, N., Ferhan, A. R., Kim, J., Majima, T., & Cho, N. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202008352 · Cited by 46
Villena, J., Li, C., Vizoso-Pinto, M. G., Sacur, J., Ren, L., & Kitazawa, H. (2021) · Microorganisms · doi:10.3390/microorganisms9040683 · Cited by 45
SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses
Carnell, G., Ciazynska, K. A., Wells, D. A., Xiong, X., Aguinam, E. T., McLaughlin, S. H., Mallery, D. L., Ebrahimi, S., Ceron‐Gutierrez, L., Asbach, B., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00203-21 · Cited by 46
Abir, T., Kalimullah, N. A., Osuagwu, U. L., Yazdani, D. M. N., Husain, T., Goson, P. C., Basak, P., Rahman, M. A., Mamun, A. A., Permarupan, P. Y., et al. (2021) · Annals of Global Health · doi:10.5334/aogh.3269 · Cited by 51
Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design
Cai, X., Li, J. J., Liu, T., Brian, O., & Li, J. (2021) · Briefings in Functional Genomics · doi:10.1093/bfgp/elab027 · Cited by 47
Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic
Yap, C., Ali, A., Prabhakar, A., Prabhakar, A., Pal, A., Lim, Y. Y., & Kakodkar, P. (2021) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355211059791 · Cited by 48
Li, J., Liu, B., Tang, X., Wu, Z., Lu, J., Liang, C., Hou, S., Zhang, L., Li, T., Zhao, W., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.04.042 · Cited by 46
Chowdhury, S., Chowdhury, J. T., Ahmed, S. F., Agarwal, P., Badruddin, I. A., & Kamangar, S. (2021) · AIMS Mathematics · doi:10.3934/math.2022147 · Cited by 45
COVID-19: systemic pathology and its implications for therapy
Shen, Q., Li, J., Zhang, Z., Guo, S., Wang, Q., An, X., & Chang, H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.65911 · Cited by 51
DeepNeo: a webserver for predicting immunogenic neoantigens
Kim, J. Y., Bang, H., Noh, S.-J., & Choi, J. K. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad275 · Cited by 44
RNA 3D Structure Prediction Using Coarse-Grained Models
Li, J., & Chen, S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.720937 · Cited by 45
Nanoparticles in clinical trials of COVID-19: An update
Rauf, A., Abu‐Izneid, T., Khalil, A. A., Hafeez, N., Olatunde, A., Rahman, M. M., Semwal, P., Al-Awthan, Y. S., Bahattab, O. S., Khan, I. N., et al. (2022) · International Journal of Surgery · doi:10.1016/j.ijsu.2022.106818 · Cited by 47
Nurses' smoking behaviour related to cessation practice.
Slater, P. F., McElwee, G., Fleming, P. J., & McKenna, H. (2006) · PubMed · Cited by 45
mRNA Vaccines against Flaviviruses
Wollner, C. J., & Richner, J. M. (2021) · Vaccines · doi:10.3390/vaccines9020148 · Cited by 44
Al-Karmalawy, A. A., Soltane, R., Elmaaty, A. A., Tantawy, M. A., Antar, S. A., Yahya, G., Chrouda, A., Pashameah, R. A., Mustafa, M., Mraheil, M. A., et al. (2021) · Vaccines · doi:10.3390/vaccines9111317 · Cited by 43
Pandemic-response adenoviral vector and RNA vaccine manufacturing
Kis, Z., Tak, K., Ibrahim, D., Papathanasiou, M. M., Chachuat, B., Shah, N., & Kontoravdi, C. (2022) · npj Vaccines · doi:10.1038/s41541-022-00447-3 · Cited by 52
Respiratory illness virus infections with special emphasis on COVID-19
Gandhi, L., Maisnam, D., Rathore, D., Chauhan, P., Bonagiri, A., & Venkataramana, M. (2022) · European journal of medical research · doi:10.1186/s40001-022-00874-x · Cited by 49
Choi, J. H., Jun, M. S., Jeon, J. Y., Kim, H.-S., Kim, Y. K., Jeon, C. H., Choi, S. H., Kim, D. S., Han, M., & Oh, J. W. (2023) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0118 · Cited by 44
Studying SARS-CoV-2 infectivity and therapeutic responses with complex organoids
Chen, K. G., Park, K., & Spence, J. R. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00721-x · Cited by 45
Structure‐guided envelope trimer design in HIV‐1 vaccine development: a narrative review
Derking, R., & Sanders, R. W. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25797 · Cited by 46
Altered IgG glycosylation at COVID‐19 diagnosis predicts disease severity
Vicente, M. M., Alves, I., Gaifem, J., Rodrigues, C. S., Fernandes, Â., Dias, A. M., Štambuk, J., Pribić, T., Oliveira, P., Ferreira‐da‐Silva, F., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202149491 · Cited by 45
Salleh, M. Z., Norazmi, M. N., & Deris, Z. Z. (2022) · PeerJ · doi:10.7717/peerj.13083 · Cited by 45
Burn, E., Li, X., Kostka, K., Stewart, H. M., Reich, C., Seager, S., Duarte‐Salles, T., Fernandez‐Bertolin, S., Aragón, M., Reyes, C., et al. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5419 · Cited by 43
Updated and Validated Pan-Coronavirus PCR Assay to Detect All Coronavirus Genera
Holbrook, M. G., Anthony, S. J., Navarrete‐Macias, I., Bestebroer, T. M., Munster, V. J., & van Doremalen, N. (2021) · Viruses · doi:10.3390/v13040599 · Cited by 43
Nasally inhaled therapeutics and vaccination for COVID‐19: Developments and challenges
Xi, J., Lei, L. R., Zouzas, W., & Si, X. A. (2021) · MedComm · doi:10.1002/mco2.101 · Cited by 45
Wang, X., Mahmood, S. F., Jin, F., Cheah, W. K., Ahmad, M., Sohail, M. A., Ahmad, W., Suppan, V. K. L., Sayeed, M. A., Luxmi, S., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2088406 · Cited by 43
Yasamineh, S., Kalajahi, H. G., Yasamineh, P., Gholizadeh, O., Youshanlouei, H. R., Matloub, S. K., Mozafari, M., Jokar, E., Yazdani, Y., & Dadashpour, M. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02944-7 · Cited by 44
Injectable Hydrogel Mucosal Vaccine Elicits Protective Immunity against Respiratory Viruses
Fu, W., Guo, M., Zhou, X., Wang, Z., Sun, J., An, Y., Guan, T., Hu, M., Li, J., Chen, Z., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c00155 · Cited by 47
Plitidepsin: a Repurposed Drug for the Treatment of COVID-19
Martı́nez, M. Á. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00200-21 · Cited by 43
Si, R., Yao, Y., Zhang, X., Lu, Q., & Aziz, N. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.702699 · Cited by 43
The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection
Hu, J., Stojanović, J., Yasamineh, S., Yasamineh, P., Karuppannan, S. K., Dowlath, M. J. H., & Serati‐Nouri, H. (2021) · Archives of Virology · doi:10.1007/s00705-021-05152-5 · Cited by 43
Dubey, A. K., Chabert, G. L., Carriero, A., Paschè, A., Danna, P. S. C., Agarwal, S., Mohanty, L., Nillmani, Sharma, N., Yadav, S., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13111954 · Cited by 42
Lien, C.-E., Lin, Y.-J., Chen, C., Lian, W., Kuo, T.-Y., Campbell, J. D., Traquina, P., Liu, L. T.-C., Liu, L. T.-C., Chuang, Y.-S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88283-8 · Cited by 42
Chousa, J. P., Cabarcos, Á. L., Quiñoá‐Piñeiro, L., & Pérez-Pico, A. M. (2021) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2021.121365 · Cited by 49
Khoury, L. E., Jing, Z., Cuzzolin, A., Deplano, A., Loco, D., Sattarov, B., Hédin, F., Wendeborn, S. V., Ho, C. M. W., Ahdab, D. E., et al. (2022) · Chemical Science · doi:10.1039/d1sc05892d · Cited by 44
Mikolajek, H., Weckener, M., Brotzakis, Z. F., Huo, J., Dalietou, E. V., Bas, A. L., Sormanni, P., Harrison, P. J., Ward, P. N., Truong, S. D., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205412119 · Cited by 39
Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective
Huang, Y., Sun, H., Yu, H. J., Li, S., Zheng, Q., & Xia, N. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa028 · Cited by 40
Slamanig, S., & Nolte, M. A. (2021) · Cells · doi:10.3390/cells10061508 · Cited by 44
Jahn, B., Sroczynski, G., Bicher, M., Rippinger, C., Mühlberger, N., Santamaria, J., Urach, C., Schomaker, M., Stojkov, I., Schmid, D., et al. (2021) · Vaccines · doi:10.3390/vaccines9050434 · Cited by 42
Determinants of access to the SARS-CoV-2 vaccine: a preliminary approach
de Oliveira, B. R. B., Sobral, A. I. G. D. P., Marinho, M., Sobral, M. F. F., Melo, A. D. S., & Duarte, G. B. (2021) · International Journal for Equity in Health · doi:10.1186/s12939-021-01520-4 · Cited by 41
Metadata
- Authors
- Krammer, F.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Krammer, Florian
- ORCID
- Krammer, Florian
- Venue
- Nature
- Published
- 2020-09-23
- Volume
- 586
- Issue
- 7830
- Pages
- 516-527
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3087924281
- Cited by
- 2,098
- References
- 101
- Citations by year
- 2026: 91 · 2025: 147 · 2024: 173 · 2023: 287 · 2022: 538 · 2021: 747 · 2020: 112
- FWCI
- 19.97
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (cc-by)
- Funders
- JPB Foundation (2020-215611, HHSN272201400008C, 75N93019C00051)
- Open Philanthropy Project (#2020-215611, 75N93019C00051, HHSN272201400008C)
- National Institute of Allergy and Infectious Diseases (HHSN272201400008C), 75N93019C00051, 2020-215611, HHSN272201800048C)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- SARS-CoV-2, COVID-19 vaccines, vaccine development, vaccine candidate, clinical trials, animal studies, vaccine safety, vaccine efficacy, COVID-19 pandemic
- MeSH terms
- Drug Development, COVID-19, COVID-19 Vaccines, Animals, Clinical Trials as Topic, Drug Industry, Humans, Pneumonia, Viral, Viral Vaccines, Coronavirus Infections, Immunity, Mucosal, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
